SGMO - サンガモ・セラピュ―ティクス (Sangamo Therapeutics Inc.)

SGMOのニュース

   Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors  2020/09/11 12:30:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan, an accomplished biotechnology executive, to the Company's Board of Directors. "We are pleased to welcome Kenneth to the Sangamo Board of Directors," said Sandy Macrae, Chief Executive Officer of Sangamo. "We believe that Kenneth’s 25 years of clinical development and executive leadership experience, as well as his current focus on the t
   Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences  2020/09/02 20:15:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences: Wells Fargo 2020 Virtual Healthcare Conference Presentation Date: Thursday, September 10th at 3:20 p.m. Eastern Time Cantor Virtual Global Healthcare Conference Presentation Date: Tuesday, September 15th at 3:20 p.m. Eastern Time Morgan Stanley 18th Annual Global Healthcare Conference Presentation Date: Frid
   How Much Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Paying Its CEO?  2020/09/01 19:47:48 Yahoo Finance
Sandy Macrae became the CEO of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in 2016, and we think it's a good time to look…
   The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs  2020/08/07 11:34:07 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 6) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (announced introduction of AditxtScore for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biocept Inc (NASDAQ: BIOC ) (announced an agreement with Aegea for a highly sensitive PCR-based assay designed by the latter for detecting the COVID-19 virus) DarioHealth Corp (NASDAQ: DRIO ) Denali Therapeutics Inc (NASDAQ: DNLI )( announced selection of candidate to enter Phase 3 study in Parkinson's disease) Editas Medicine Inc (NASDAQ: EDIT )(moved on M&A speculation) Emergent Biosolutions Inc (NYSE: EBS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Natera Inc (NASDAQ: NTRA ) PDL BioPharma Inc (NASDAQ: PDLI ) Sangamo Therapeutics Inc (NASDAQ: SGMO ) (reacted to its second-quarter results) Shockwave Medical Inc (NASDAQ: SWAV ) SurModics, Inc. (NASDAQ: SRDX )(reacted to its second-quarter results) Twist Bioscience Corp (NASDAQ: TWST ) Unity Biotechnology Inc (NASDAQ: UBX ) Zoetis Inc (NYSE: ZTS ) (reacted to its second-quarter results) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 6) Nkarta Inc (NASDAQ: NKTX ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX )(announced its second-quarter results) Stocks In Focus Zosano Clinches Distribution Deal For Investigational Migraine Patch Zosano Pharma Corp (NASDAQ: ZSAN ) said it has partnered with Eversana commercialize and distribute Qtrypta in the U.S.
   Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results  2020/08/05 20:01:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights. “We are very excited about our global collaboration agreement announced with Novartis last week. This is our second impactful partnership announced this year, and we believe it affirms the value our industry sees in our zinc finger technology,” said Sandy Macrae, CEO of Sangamo. “By advancing our robust par
   The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs  2020/08/07 11:34:07 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 6) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (announced introduction of AditxtScore for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biocept Inc (NASDAQ: BIOC ) (announced an agreement with Aegea for a highly sensitive PCR-based assay designed by the latter for detecting the COVID-19 virus) DarioHealth Corp (NASDAQ: DRIO ) Denali Therapeutics Inc (NASDAQ: DNLI )( announced selection of candidate to enter Phase 3 study in Parkinson's disease) Editas Medicine Inc (NASDAQ: EDIT )(moved on M&A speculation) Emergent Biosolutions Inc (NYSE: EBS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Natera Inc (NASDAQ: NTRA ) PDL BioPharma Inc (NASDAQ: PDLI ) Sangamo Therapeutics Inc (NASDAQ: SGMO ) (reacted to its second-quarter results) Shockwave Medical Inc (NASDAQ: SWAV ) SurModics, Inc. (NASDAQ: SRDX )(reacted to its second-quarter results) Twist Bioscience Corp (NASDAQ: TWST ) Unity Biotechnology Inc (NASDAQ: UBX ) Zoetis Inc (NYSE: ZTS ) (reacted to its second-quarter results) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 6) Nkarta Inc (NASDAQ: NKTX ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX )(announced its second-quarter results) Stocks In Focus Zosano Clinches Distribution Deal For Investigational Migraine Patch Zosano Pharma Corp (NASDAQ: ZSAN ) said it has partnered with Eversana commercialize and distribute Qtrypta in the U.S.
   Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results  2020/08/05 20:01:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights. “We are very excited about our global collaboration agreement announced with Novartis last week. This is our second impactful partnership announced this year, and we believe it affirms the value our industry sees in our zinc finger technology,” said Sandy Macrae, CEO of Sangamo. “By advancing our robust par
   Collaborating to explore new gene regulation therapies | Novartis  2020/07/30 13:34:00 Novartis
Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.
   Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast  2020/07/29 20:15:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2020 financial results after the market closes on Wednesday, August 5, 2020. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business updat
   Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference  2020/05/29 13:00:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m. ET. The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. About Sangamo Therapeutics Sangamo Therapeutics is committed to translating ground-breaking s
   Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference  2020/05/29 13:00:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m. ET. The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. About Sangamo Therapeutics Sangamo Therapeutics is committed to translating ground-breaking s
   Sangamo Therapeutics Announces Participation at the Bank of America 2020 Health Care Conference  2020/05/12 13:15:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Bank of America 2020 Health Care Conference on Thursday, May 14 at 4:20 p.m. ET. The audio presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. About Sangamo Therapeutics Sangamo Therapeutics is committed to translating ground
   Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates  2020/05/11 21:15:05 Zacks Investment Research
Sangamo (SGMO) delivered earnings and revenue surprises of -60.87% and -57.78%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Sangamo Therapeutics Reports Business Highlights and First Quarter 2020 Financial Results  2020/05/11 20:01:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported first quarter 2020 financial results and recent business highlights. “I’m proud of how the Sangamo team has worked together through the unusual circumstances presented by the COVID-19 pandemic,” said Sandy Macrae, CEO of Sangamo. “While adhering to governmental workplace guidelines, we have sought to minimize disruptions to the progress of our research in the labs, our clinic
   Is Sangamo Therapeutics (SGMO) Stock Outpacing Its Medical Peers This Year?  2020/05/05 15:30:15 Zacks Investment Research
Is (SGMO) Outperforming Other Medical Stocks This Year?

calendar